Stacey C Sigmon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11240379/publications.pdf

Version: 2024-02-01

89 papers 2,892 citations

30 h-index 51 g-index

90 all docs 90 docs citations

90 times ranked 2571 citing authors

#	Article	IF	Citations
1	Community Reinforcement Therapy for Cocaine-Dependent Outpatients. Archives of General Psychiatry, 2003, 60, 1043.	13.8	180
2	Access to Treatment for Opioid Dependence in Rural America. JAMA Psychiatry, 2014, 71, 359.	6.0	168
3	Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact. Journal of Addiction Medicine, 2017, 11, 286-292.	1.4	162
4	Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder. JAMA Internal Medicine, 2018, 178, 764.	2.6	148
5	The use of financial incentives in promoting smoking cessation. Preventive Medicine, 2012, 55, S24-S32.	1.6	113
6	Addiction Potential of Cigarettes With Reduced Nicotine Content in Populations With Psychiatric Disorders and Other Vulnerabilities to Tobacco Addiction. JAMA Psychiatry, 2017, 74, 1056.	6.0	101
7	Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice. American Journal of Drug and Alcohol Abuse, 2012, 38, 187-199.	1.1	100
8	Characterizing the Emerging Population of Prescription Opioid Abusers. American Journal on Addictions, 2006, 15, 208-212.	1.3	84
9	Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: A feasibility study Experimental and Clinical Psychopharmacology, 2000, 8, 509-517.	1.3	76
10	A Randomized, Double-blind Evaluation of Buprenorphine Taper Duration in Primary Prescription Opioid Abusers. JAMA Psychiatry, 2013, 70, 1347.	6.0	72
11	Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: cerebral blood flow velocity, quantitative EEG, and subjective effects. Psychopharmacology, 2009, 204, 573-585.	1.5	70
12	Interim Buprenorphine vs. Waiting List for Opioid Dependence. New England Journal of Medicine, 2016, 375, 2504-2505.	13.9	67
13	The Untapped Potential of Office-Based Buprenorphine Treatment. JAMA Psychiatry, 2015, 72, 395.	6.0	65
14	A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients Experimental and Clinical Psychopharmacology, 2010, 18, 37-50.	1.3	61
15	Does Tobacco Abstinence Decrease Reward Sensitivity? A Human Laboratory Test. Nicotine and Tobacco Research, 2017, 19, 677-685.	1.4	60
16	VOUCHERâ€BASED CONTINGENT REINFORCEMENT OF SMOKING ABSTINENCE AMONG METHADONEâ€MAINTAINED PATIENTS: A PILOT STUDY. Journal of Applied Behavior Analysis, 2008, 41, 527-538.	2.2	58
17	Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug and Alcohol Dependence, 2004, 73, 11-22.	1.6	56
18	Psychosocial Interventions for Adults with Severe Mental Illnesses and Co-Occurring Substance Use Disorders. Journal of Dual Diagnosis, 2005, 1, 57-82.	0.7	56

#	Article	IF	CITATIONS
19	The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review. Drug and Alcohol Dependence, 2011, 119, 1-9.	1.6	53
20	An injection depot formulation of buprenorphine: extended biodelivery and effects. Addiction, 2006, 101, 420-432.	1.7	52
21	Increases in Body Mass Index Following Initiation of Methadone Treatment. Journal of Substance Abuse Treatment, 2015, 51, 59-63.	1.5	49
22	Voucher-based contingent reinforcement of marijuana abstinence among individuals with serious mental illness. Journal of Substance Abuse Treatment, 2006, 30, 291-295.	1.5	48
23	Opioid Overdose Experience, Risk Behaviors, and Knowledge in Drug Users from a Rural Versus an Urban Setting. Journal of Substance Abuse Treatment, 2016, 71, 1-7.	1.5	47
24	Associations between opioid and nicotine dependence in nationally representative samples of United States adult daily smokers. Drug and Alcohol Dependence, 2018, 186, 167-170.	1.6	45
25	Changes in Cigarette Consumption With Reduced Nicotine Content Cigarettes Among Smokers With Psychiatric Conditions or Socioeconomic Disadvantage. JAMA Network Open, 2020, 3, e2019311.	2.8	42
26	Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction, 2004, 99, 1439-1449.	1.7	40
27	Using behavioral economic theory to increase use of effective contraceptives among opioid-maintained women at risk of unintended pregnancy. Preventive Medicine, 2016, 92, 62-67.	1.6	38
28	Acute effects of d-amphetamine on progressive-ratio performance maintained by cigarette smoking and money. Psychopharmacology, 2003, 167, 393-402.	1.5	37
29	Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions: Table 1 Nicotine and Tobacco Research, 2015, 17, 955-959.	1.4	36
30	Contingency Management Interventions for HIV, Tuberculosis, and Hepatitis Control Among Individuals With Substance Use Disorders: A Systematized Review. Journal of Substance Abuse Treatment, 2017, 72, 117-125.	1.5	33
31	Use of a low-cost incentive intervention to improve counseling attendance among methadone-maintained patients. Journal of Substance Abuse Treatment, 2005, 29, 253-258.	1.5	32
32	Response to varying the nicotine content of cigarettes in vulnerable populations: an initial experimental examination of acute effects. Psychopharmacology, 2017, 234, 89-98.	1.5	32
33	Bridging waitlist delays with interim buprenorphine treatment: Initial feasibility. Addictive Behaviors, 2015, 51, 136-142.	1.7	31
34	Brief buprenorphine detoxification for the treatment of prescription opioid dependence: A pilot study. Addictive Behaviors, 2009, 34, 304-311.	1.7	27
35	Response to reduced nicotine content cigarettes among smokers differing in tobacco dependence severity. Preventive Medicine, 2018, 117, 15-23.	1.6	27
36	Characterizing opioid withdrawal during double-blind buprenorphine detoxification. Drug and Alcohol Dependence, 2015, 151, 47-55.	1.6	26

3

#	Article	IF	CITATIONS
37	Financial incentives to promote extended smoking abstinence in opioidâ€maintained patients: a randomized trial. Addiction, 2016, 111, 903-912.	1.7	26
38	Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement Experimental and Clinical Psychopharmacology, 2007, 15, 1-20.	1.3	22
39	Higher smoking prevalence among United States adults with co-occurring affective and drug use diagnoses. Addictive Behaviors, 2019, 99, 106112.	1.7	21
40	Characterizing and improving HIV and hepatitis knowledge among primary prescription opioid abusers. Drug and Alcohol Dependence, 2013, 133, 625-632.	1.6	20
41	Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential. Addiction, 2017, 112, 386-387.	1.7	20
42	Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms Experimental and Clinical Psychopharmacology, 2018, 26, 403-409.	1.3	20
43	Fentanyl exposure among patients seeking opioid treatment. Journal of Substance Abuse Treatment, 2019, 96, 23-25.	1.5	19
44	Evaluation of ongoing oxycodone abuse among methadone-maintained patients. Journal of Substance Abuse Treatment, 2008, 35, 451-456.	1.5	17
45	Preliminary validity of the modified Cigarette Evaluation Questionnaire in predicting the reinforcing effects of cigarettes that vary in nicotine content Experimental and Clinical Psychopharmacology, 2017, 25, 473-478.	1.3	16
46	Interim treatment: Bridging delays to opioid treatment access. Preventive Medicine, 2015, 80, 32-36.	1.6	15
47	A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study. Drug and Alcohol Dependence, 2018, 190, 224-228.	1.6	15
48	Improving medicaid health incentives programs: Lessons from substance abuse treatment research. Preventive Medicine, 2014, 63, 87-89.	1.6	14
49	Effects of Smoking Cessation on Illicit Drug Use among Opioid Maintenance Patients: A Pilot Study. Journal of Drug Issues, 2009, 39, 313-327.	0.6	13
50	Contingency management for behavior change: Applications to promote brief smoking cessation among opioid-maintained patients Experimental and Clinical Psychopharmacology, 2011, 19, 20-30.	1.3	13
51	Cocaine Abstinence During Methadone Maintenance: Effects of Repeated Brief Exposure to Voucher-Based Reinforcement Experimental and Clinical Psychopharmacology, 2004, 12, 269-275.	1.3	11
52	Caffeine choice prospectively predicts positive subjective effects of caffeine and d-amphetamine. Drug and Alcohol Dependence, 2011, 118, 341-348.	1.6	11
53	Co-occurring vulnerabilities and menthol use in U.S. young adult cigarette smokers: Findings from Wave 1 of the PATH Study, 2013–2014. Preventive Medicine, 2018, 117, 43-51.	1.6	11
54	Efficacy and Cost-Benefit of Onsite Contraceptive Services With and Without Incentives Among Women With Opioid Use Disorder at High Risk for Unintended Pregnancy. JAMA Psychiatry, 2021, 78, 1071-1078.	6.0	11

#	Article	IF	CITATIONS
55	Spontaneous reductions in smoking during double-blind buprenorphine detoxification. Addictive Behaviors, 2014, 39, 1353-1356.	1.7	10
56	Behavioral risk assessment for infectious diseases (BRAID): Self-report instrument to assess injection and noninjection risk behaviors in substance users. Drug and Alcohol Dependence, 2016, 168, 69-75.	1.6	10
57	Evaluating the utility of the modified cigarette evaluation questionnaire and cigarette purchase task for predicting acute relative reinforcing efficacy of cigarettes varying in nicotine content. Drug and Alcohol Dependence, 2019, 197, 56-64.	1.6	10
58	Perceptions of long-acting reversible contraception among women receiving medication for opioid use disorder in Vermont. Contraception, 2020, 101, 333-337.	0.8	10
59	Opioid use disorder treatment in rural settings: The primary care perspective. Preventive Medicine, 2021, 152, 106765.	1.6	10
60	Response to Reduced Nicotine Content in Vulnerable Populations: Effect of Menthol Status. Tobacco Regulatory Science (discontinued), 2019, 5, 135-142.	0.2	10
61	Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers. Addictive Behaviors, 2015, 42, 189-193.	1.7	9
62	Innovations in efforts to expand treatment for opioid use disorder. Preventive Medicine, 2019, 128, 105818.	1.6	9
63	Potential Moderating Effects of Psychiatric Diagnosis and Symptom Severity on Subjective and Behavioral Responses to Reduced Nicotine Content Cigarettes. Nicotine and Tobacco Research, 2019, 21, S29-S37.	1.4	8
64	Examining Age as a Potential Moderator of Response to Reduced Nicotine Content Cigarettes in Vulnerable Populations. Nicotine and Tobacco Research, 2019, 21, S49-S55.	1.4	8
65	Development of a Self-Report Measure of Reward Sensitivity: A Test in Current and Former Smokers. Nicotine and Tobacco Research, 2017, 19, 723-728.	1.4	7
66	Tobacco withdrawal among opioid-dependent smokers Experimental and Clinical Psychopharmacology, 2018, 26, 119-124.	1.3	7
67	The Impact of the Covid-19 Pandemic on Smoking Among Vulnerable Populations. Nicotine and Tobacco Research, 2023, 25, 282-290.	1.4	7
68	Additive burdens of malnutrition, poverty, and substance abuse. Lancet, The, 2016, 388, 1879-1880.	6.3	6
69	Relating individual differences in nicotine dependence severity to underpinning motivational and pharmacological processes among smokers from vulnerable populations. Preventive Medicine, 2020, 140, 106189.	1.6	6
70	Investigating tobacco withdrawal in response to reduced nicotine cigarettes among smokers with opioid use disorder and other vulnerabilities Experimental and Clinical Psychopharmacology, 2020, 28, 714-723.	1.3	6
71	Promoting smoking abstinence among patients with chronic obstructive pulmonary disease: Initial feasibility. Preventive Medicine Reports, $2018, 11, 176-179$.	0.8	5
72	Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults. Drug and Alcohol Dependence, 2020, 208, 107879.	1.6	5

#	Article	IF	CITATIONS
73	Within-subject evaluation of interim buprenorphine treatment during waitlist delays. Drug and Alcohol Dependence, 2021, 220, 108532.	1.6	5
74	Cumulative vulnerabilities as a potential moderator of response to reduced nicotine content cigarettes. Preventive Medicine, 2021, 152, 106714.	1.6	5
75	Effects of Reduced Nicotine Content Cigarettes on Fractional Exhaled Nitric Oxide and Self-Reported Respiratory Health Outcomes Among Smokers With Psychiatric Conditions or Socioeconomic Disadvantage. Nicotine and Tobacco Research, 2022, 24, 135-140.	1.4	5
76	Sucrose subjective response and eating behaviors among individuals with opioid use disorder. Drug and Alcohol Dependence, 2021, 227, 109017.	1.6	5
77	Reduced Nicotine Content Cigarettes and Cannabis Use in Vulnerable Populations. Tobacco Regulatory Science (discontinued), 2018, 4, 84-91.	0.2	5
78	Voucher-based contingency management in the treatment of substance use disorders, 2013, , 481-500.		4
79	Response to reduced nicotine content cigarettes among smokers with chronic health conditions. Preventive Medicine Reports, 2018, 12, 321-329.	0.8	4
80	Posttraumatic stress disorder in individuals seeking treatment for opioid use disorder in Vermont. Preventive Medicine, 2021, 152, 106817.	1.6	4
81	Feasibility of an interactive voice response system for daily monitoring of illicit opioid use during buprenorphine treatment Psychology of Addictive Behaviors, 2018, 32, 956-960.	1.4	4
82	National Trends in Suicide Thoughts and Behavior among US Adults with Opioid Use Disorder from 2015 to 2020. Substance Use and Misuse, 2022, 57, 876-885.	0.7	4
83	Implications of behavioral momentum for understanding the behavioral pharmacology of abused drugs. Behavioral and Brain Sciences, 2000, 23, 101-101.	0.4	3
84	Examining effects of unit price on preference for reduced nicotine content cigarettes and smoking rate. Preventive Medicine, 2019, 128, 105823.	1.6	3
85	Reasons for non-medical use of prescription opioids among young adults: Role of educational status. Preventive Medicine, 2019, 128, 105684.	1.6	3
86	Potential Moderating Effects of Sex/Gender on the Acute Relative Reinforcing and Subjective Effects of Reduced Nicotine Content Cigarettes in Vulnerable Populations. Nicotine and Tobacco Research, 2020, 22, 878-884.	1.4	3
87	Impact of Current Pain Status on Low-Barrier Buprenorphine Treatment Response Among Patients with Opioid Use Disorder. Pain Medicine, 2021, 22, 1205-1212.	0.9	2
88	Editorial. The prescription opioid abuse epidemic in rural America: A look at how it begins. Journal of Opioid Management, 2014, 10, 225-226.	0.2	1
89	Contingency Management in Drug Dependence. , 2014, , 1-7.		0